Table 4.
Distribution frequency of the clinical status and GAS5 rs145204276 genotype frequencies in 159 female UCC patients.
| Variable | GAS5 (rs145204276) | |||
|---|---|---|---|---|
| Ins/Ins (%) (n = 68) | Ins/Del + Del/Del (%) (n = 91) | OR (95% CI) | p Value | |
| Stage | ||||
| Non muscle invasive tumor | 38 (55.9%) | 46 (50.5%) | 1.000 (reference) | |
| Muscle invasive tumor | 30 (44.1%) | 45 (49.5%) | 1.239 (0.659–2.329) | 0.505 |
| Tumor T status | ||||
| Ta | 17 (25.0%) | 9 (9.9%) | 1.000 (reference) | |
| T1-T2 | 28 (41.2%) | 50 (54.9%) | 3.373 (1.329–8.558) | 0.009 * |
| T3-T4 | 23 (33.8%) | 32 (35.2%) | 2.628 (1.001–6.929) | 0.048 * |
| Lymph node status | ||||
| N0 | 60 (88.2%) | 81 (89.0%) | 1.000 (reference) | |
| N1 + N2 | 8 (11.8%) | 10 (11.0%) | 0.926 (0.345–2.486) | 0.879 |
| Metastasis | ||||
| M0 | 68 (100%) | 88 (96.7%) | 1.000 (reference) | |
| M1 | 0 (0.0%) | 3 (3.3%) | 0.131 | |
| Histopathologic grading | ||||
| Low grade | 9 (13.2%) | 5 (5.5%) | 1.000 (reference) | |
| High grade | 59 (86.8%) | 86 (94.5%) | 2.624 (0.837–8.223) | 0.088 |
Bold font indicates statistical significance (* p < 0.05); The odds ratios (ORs) with their 95% confidence intervals were estimated by logistic regression models.